MétaCan
Menu
Retour à la cohorte
Enregistrement W2407340489 · doi:10.1158/2326-6074.cricimteatiaacr15-b082

Abstract B082: Reovirus treated NK cells exhibit enhanced cetuximab mediated antibody- dependent cellular cytotoxicity against colorectal cancer cell lines

2016· article· en· W2407340489 sur OpenAlexaff
Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Holbrook E. Kohrt

Notice bibliographique

RevueCancer Immunology Research · 2016
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueVirus-based gene therapy research
Établissements canadiensOncolytics Biotech (Canada)
Organismes subventionnairesnon disponible
Mots-clésAntibody-dependent cell-mediated cytotoxicityCetuximabCytotoxicityCytotoxic T cellCancer researchAntibodyInterleukin 12Immune systemCancer cellChemistryImmunologyBiologyCancerMonoclonal antibodyIn vitroBiochemistry

Résumé

récupéré en direct d'OpenAlex

Abstract The naturally occurring oncolytic virus, reovirus, exhibits cytotoxic effects on cancer cells with an activated RAS-signaling pathway. In addition to their direct cytotoxic effects they also activate the innate and adaptive immune responses to facilitate tumor clearance. Reovirus is safe, and currently is in clinical testing for the treatment of multiple clinical cancer histologies. NK cells are innate immune effectors that mediate antibody dependent cellular cytotoxicity (ADCC) against tumor cells. Here we investigated the direct effect of reovirus on NK cell mediated ADCC against two EGFR (Epidermal Growth Factor) positive colorectal cancer cell lines: DLD-1 (KRAS mut) and Caco-2 (KRAS WT). NK cells isolated from human PBMCs were cultured with 1pfu of reovirus for 12 hrs. These reovirus treated NK cells were co-cultured with DLD-1 cells or Caco2 cells (E:T-1:1) coated with increasing concentrations anti-EGFR antibody cetuximab. ADCC was measured after 4hrs using a lactate dehydrogenase (LDH) based cytotoxicity assay. We observed that the reovirus treated NK cells (Reo-NK cells) exhibited a ~16-fold increase in cytotoxicity against DLD-1 (16.3% ±1.5, n=3) compared to untreated NK cells (NK cells), even in the absence of any cetuximab antibody. In the presence of cetuximab antibody, NK cells showed a dose dependent increase in ADCC, with maximum ADCC, observed at 0.1 µg/ml of cetuximab (DLD-NK: 33.4%± 7.1, Caco2-NK: 5.7%± 0.071, n=3). Interestingly, Reo-NK cells showed maximum ADCC even at 0.01 µg /ml of cetuximab (DLD1-Reo-NK: 39.1±7.4, DLD1-NK: 26.7±2.4%; Caco2-Reo-NK: 9.2±0.4, Caco2-NK: 4.0±0.8, n=3). To further investigate the factors contributing to the increased cytotoxic potential of Reo-NK cells we performed flow cytometry analysis to determine the expression of activation and degranulation markers on NK cells. We observed that in presence of tumor cells Reo-NK cells exhibited a 2-fold increased expression of activation marker CD69 when compared to untreated NK cells (Reo-NK:70.4%, NK:35.2%). A similar increase was also observed when Reo-NK cells were co-cultured with target cells coated with 0.01 µg /ml of cetuximab (Reo-NK: 85.1%; NK: 72.7%). Expression of the degranulation marker CD107a is increased on NK cells during ADCC. There was a ~3-fold increase in expression of CD107a on Reo-NK cells when compared to NK cells (Reo-NK: 14.6%; NK: 4.45%). To further investigate if perforin-based cytotoxicity was responsible for the increased ADCC by Reo-NK cells, we treated Reo-NK and NK cells with concanamycin A (CMA), an inhibitor of perforin. We found that CMA treatment reduced Reo-NK cell mediated ADCC by 1.5 fold (CMA treated-28.2%, CMA untreated 18.9%) indicating a perforin-mediated cytotoxicity contributes to the increased cytotoxicity of Reo-NK cells. Thus, in this study our results demonstrated that human NK cells when treated with reovirus show increases in activation, degranulation and cytotoxicity when compared to untreated NK cells. Importantly, reovirus treated NK cells lowered the threshold of cetuximab required to achieve maximum ADCC. We propose that reovirus activated NK cells are a potential candidate for cell based immunotherapy in combination with FDA approved tumor targeting antibodies. Further studies are ongoing to investigate the underlying mechanisms that contribute to the increase in cytotoxicity by NK cells treated with reovirus. Citation Format: Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Holbrook Kohrt. Reovirus treated NK cells exhibit enhanced cetuximab mediated antibody- dependent cellular cytotoxicity against colorectal cancer cell lines. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B082.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,001
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesMéta-épidémiologie (sens strict), Charge utile insuffisante (le modèle a refusé de juger)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: Expérimental (laboratoire)
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,041
Score d'incertitude au seuil1,000

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0010,000
Méta-épidémiologie (sens strict)0,0010,000
Méta-épidémiologie (sens large)0,0010,000
Bibliométrie0,0000,001
Études des sciences et des technologies0,0000,001
Communication savante0,0000,000
Science ouverte0,0010,001
Intégrité de la recherche0,0010,001
Charge utile insuffisante (le modèle a refusé de juger)0,0020,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,029
Tête enseignante GPT0,347
Écart entre enseignants0,318 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2016
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueCancer Immunology ResearchMême sujetVirus-based gene therapy researchTravaux en français237 207